(Q46973779)

27 December 2017

title

IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients (English)

1 reference

27 December 2017

author

Luca Castagna

9

1 reference

27 December 2017

author name string

M Magagnoli

1

1 reference

27 December 2017

M Spina

2

1 reference

27 December 2017

M Balzarotti

3

1 reference

27 December 2017

I Timofeeva

4

1 reference

27 December 2017

L Isa

5

1 reference

27 December 2017

M Michieli

6

1 reference

27 December 2017

R Capizzuto

7

1 reference

27 December 2017

E Morenghi

8

1 reference

27 December 2017

U Tirelli

10

1 reference

27 December 2017

A Santoro

11

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

27 December 2017

Bone Marrow Transplantation

published in

1 reference

27 December 2017

volume

40

1 reference

27 December 2017

issue

11

1 reference

27 December 2017

page(s)

1019-1025

1 reference

27 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705862

exact match

0 references

cites work

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

What is the best option to cure patients with resistant/relapsing Hodgkin's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

7 January 2021

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

7 January 2021

Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

7 January 2021

VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

7 January 2021

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

7 January 2021

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

7 January 2021

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705862

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705862

1 reference

27 December 2017

Dimensions Publication ID

1004615394

0 references

1 reference

27 December 2017